Literature DB >> 24861130

Comments on "Biofilms of Candida albicans serotypes A and B differ in their sensitivity to photodynamic therapy".

Mariusz Grinholc1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24861130      PMCID: PMC4598344          DOI: 10.1007/s10103-014-1591-7

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


× No keyword cloud information.
Dear Editor, In the April 2014 issue of the online-first article, Rossoni et al. [1] reported that Candida albicans serotype B is more sensitive to photodynamic treatment than serotype A. As we know, significant variation among particular strains within the same species in response to the photodynamic treatment exists [2]. The differences can reach several logs in survival of viable counts. We have previously shown that taking into consideration the genetic background of microorganisms, i.e., Staphylococcus aureus, within the same closely related strains, assigned as a single epidemic clone, we can identify strains that are highly resistant as well as highly sensitive to photodynamic inactivation (PDI) [3]. Thus, just having a sufficiently large database of strains, one can properly infer about the importance of a particular feature in response to PDI. Unfortunately, as far as I am concerned, study of Rossoni et al. failed to include other than single reference strains of C. albicans. On the basis of single isolates, one must not drew any relevant conclusions. Moreover, switching the sensitizer can totally reverse the observed response to photodynamic treatment [4]. Consequently, such a general conclusion proposed by the authors stating that C. albicans serotype B is more sensitive to photoinactivation is not supported by the evidence, as it requires studies concerning different sensitizing agents. However, the authors have not provided any details about the effectiveness of photoinactivation against both C. albicans serotypes based on other photosensitizers. Assessing the influence of microorganism’s features on susceptibility to photoinactivation is always a complex issue. Of course, studying one sensitizer and single isolates can give us some information, but the problems in study design should not be ignored, as statistical analysis requires more numerous groups to be compared and to draw relevant conclusions. Those limitations reduce the reliability of presented results.
  4 in total

1.  Multiresistant strains are as susceptible to photodynamic inactivation as their naïve counterparts: protoporphyrin IX-mediated photoinactivation reveals differences between methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains.

Authors:  Mariusz Grinholc; Aleksandra Rapacka-Zdonczyk; Bartosz Rybak; Florian Szabados; Krzysztof P Bielawski
Journal:  Photomed Laser Surg       Date:  2014-02-14       Impact factor: 2.796

2.  Photodynamic inactivation requires innovative approach concerning numerous bacterial isolates and multicomponent sensitizing agents.

Authors:  Joanna Nakonieczna; Mariusz Grinholc
Journal:  Photodiagnosis Photodyn Ther       Date:  2012-05-10       Impact factor: 3.631

3.  Biofilms of Candida albicans serotypes A and B differ in their sensitivity to photodynamic therapy.

Authors:  Rodnei Dennis Rossoni; Júnia Oliveira Barbosa; Felipe Eduardo de Oliveira; Luciane Dias de Oliveira; Antonio Olavo Cardoso Jorge; Juliana Campos Junqueira
Journal:  Lasers Med Sci       Date:  2014-04-12       Impact factor: 3.161

4.  Association between susceptibility to photodynamic oxidation and the genetic background of Staphylococcus aureus.

Authors:  A Rapacka-Zdonczyk; A Rhod Larsen; J Empel; A Patel; M Grinholc
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-26       Impact factor: 3.267

  4 in total
  1 in total

Review 1.  Antimicrobial photodynamic therapy for inactivation of biofilms formed by oral key pathogens.

Authors:  Fabian Cieplik; Laura Tabenski; Wolfgang Buchalla; Tim Maisch
Journal:  Front Microbiol       Date:  2014-08-12       Impact factor: 5.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.